Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools

被引:86
作者
Kulmala, SM
Syrjänen, S
Shabalova, I
Petrovichev, N
Kozachenko, V
Podistov, J
Ivanchenko, O
Zakharenko, S
Nerovjna, R
Kljukina, L
Branovskaja, M
Grunberga, V
Juschenko, A
Tosi, P
Santopietro, R
Syrjänen, K
机构
[1] Fac Med, Inst Dent, Dept Oral Pathol, Turku 205020, Finland
[2] Fac Med, MediCity Res Lab, Turku 205020, Finland
[3] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow 109801, Russia
[4] Russian Acad Post Grad Med Educ, Moscow, Russia
[5] Novgorod Clin Reg Hosp, Centralised Cytol Lab, Novgorod, Russia
[6] Novgorod Female Consultat, Dept Gynaecol, Novgorod Municipal Dermatovenereol Dispensary, Novgorod, Russia
[7] Novgorod Female Consultat Outpatient Hosp, Dept Gynaecol, Novgorod, Russia
[8] Minsk State Med Inst, Dept Obstet & Gynaecol, Minsk, BELARUS
[9] Republ Ctr Clin Cytol, Res Inst Oncol & Med Radiol, Minsk, BELARUS
[10] Latvian Canc Ctr, Dept Gynaecol, Riga, Latvia
[11] Latvian Canc Ctr, Lab Cytol, Riga, Latvia
[12] Univ Siena, Dept Pathol, Siena, Italy
[13] Natl Inst Hlth, Unit Cytopathol, Lab Epidemiol & Biostat, Rome, Italy
关键词
D O I
10.1128/JCM.42.6.2470-2475.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The recognition of high-risk human papillomaviruses (HPVs) as etiological agents of cervical cancer has increased the demands to use testing for HPV for the detection of abnormal cervical smears and for cervical cancer screening. The present study compared the performance of the Hybrid Capture 2 (HC2) assay with that of PCR for the detection of significant cervical lesions in 1,511 women with different risks for HPV infections in three New Independent States of the former Soviet Union. The results showed that the level of agreement between the HC2 assay and PCR was substantial, with a kappa (Cohen) value of 0.669 (95% confidence interval [CI], 0.629 to 0.709). Of the 228 samples with discrepant results, 92 were positive by the HC2 assay but negative by PCR, whereas 136 samples were PCR positive but HC2 assay negative. The positive predictive values (PPVs) of the HC2 assay and PCR in detecting high-grade intraepithellial lesions (HSILs) were 4.5% (95% CI, 3.5 to 5.5%) and 3.6% (95% CI, 2.7 to 4.5%), respectively, and the negative predictive values (NPVs) were 99.6% (95% CI, 99.3 to 99.9%) and 99.3% (95% CI, 98.9 to 99.7%), respectively. The sensitivities of the HC2 assay and PCR for the detection of HSILs were 85.2 and 74.0%, respectively, and the specificities were 67.2 and 64.1%, respectively. In receiver operating characteristic (ROC) analysis, the performance of the HC2 assay for the detection of HSILs was excellent (P = 0.0001); the area under the ROC analysis curve was 0.858 (95% CI, 0.811 to 0.905), and the optimal balance between sensitivity (86.5%) and specificity (80%) was obtained with an HC2 assay cutoff level of 15.6 relative light units/positive control. Use of this cutoff would increase the specificity of the HC2 assay to 80.0% without compromising sensitivity. In conclusion, the results of PCR and the HC2 assay were concordant for 85% of samples, resulting in substantial reproducibility. Both tests had low PPVs, equal specificities, and equal (almost 100%) NPVs for the detection of HSILs; but the sensitivity of the HC2 assay was slightly better.
引用
收藏
页码:2470 / 2475
页数:6
相关论文
共 32 条
[1]   Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women [J].
Clavel, C ;
Masure, L ;
Bory, JP ;
Putaud, I ;
Mangeonjean, C ;
Lorenzato, M ;
Nazeyrollas, P ;
Gabriel, R ;
Quereux, C ;
Birembaut, P .
BRITISH JOURNAL OF CANCER, 2001, 84 (12) :1616-1623
[2]   HPV testing in primary screening of older women [J].
Cuzick, J ;
Beverley, E ;
Ho, L ;
Terry, G ;
Sapper, H ;
Mielzynska, I ;
Lorincz, A ;
Chan, WK ;
Krausz, T ;
Soutter, P .
BRITISH JOURNAL OF CANCER, 1999, 81 (03) :554-558
[3]   HUMAN PAPILLOMAVIRUS INFECTION IS TRANSIENT IN YOUNG-WOMEN - A POPULATION-BASED COHORT STUDY [J].
EVANDER, M ;
EDLUND, K ;
GUSTAFSSON, A ;
JONSSON, M ;
KARLSSON, R ;
RYLANDER, E ;
WADELL, G .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :1026-1030
[4]   METAANALYSIS OF PAP TEST ACCURACY [J].
FAHEY, MT ;
IRWIG, L ;
MACASKILL, P .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 141 (07) :680-689
[5]   PERSISTENCE OF TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS INFECTION AMONG CYTOLOGICALLY NORMAL WOMEN [J].
HILDESHEIM, A ;
SCHIFFMAN, MH ;
GRAVITT, PE ;
GLASS, AG ;
GREER, CE ;
ZHANG, T ;
SCOTT, DR ;
RUSH, BB ;
LAWLER, P ;
SHERMAN, ME ;
KURMAN, RJ ;
MANES, MM .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :235-240
[6]   Natural history of cervicovaginal papillomavirus infection in young women [J].
Ho, GYF ;
Bierman, R ;
Beardsley, L ;
Chang, CJ ;
Burk, RD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (07) :423-428
[7]  
Iftner Thomas, 2003, J Natl Cancer Inst Monogr, P80
[8]   A COHORT STUDY OF THE RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-2 OR GRADE-3 IN RELATION TO PAPILLOMAVIRUS INFECTION [J].
KOUTSKY, LA ;
HOLMES, KK ;
CRITCHLOW, CW ;
STEVENS, CE ;
PAAVONEN, J ;
BECKMANN, AM ;
DEROUEN, TA ;
GALLOWAY, DA ;
VERNON, D ;
KIVIAT, NB .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) :1272-1278
[9]   Human papillomavirus DNA testing for cervical cancer screening in low-resource settings [J].
Kuhn, L ;
Denny, L ;
Pollack, A ;
Lorincz, A ;
Richart, RM ;
Wright, TC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (10) :818-825
[10]  
Lorincz A, 2001, PAPILLOMAVIRUS REP, V12, P145